These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 22178143)
1. How to manage neutropenia in multiple myeloma. Palumbo A; Bladé J; Boccadoro M; Palladino C; Davies F; Dimopoulos M; Dmoszynska A; Einsele H; Moreau P; Sezer O; Spencer A; Sonneveld P; San Miguel J Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):5-11. PubMed ID: 22178143 [TBL] [Abstract][Full Text] [Related]
2. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975 [TBL] [Abstract][Full Text] [Related]
3. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473 [TBL] [Abstract][Full Text] [Related]
4. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Rusthoven J; Bramwell V; Stephenson B Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631 [TBL] [Abstract][Full Text] [Related]
5. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors]. Carrato A; Guillén-Ponce C; Grande-Pulido E Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851 [TBL] [Abstract][Full Text] [Related]
6. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156 [TBL] [Abstract][Full Text] [Related]
7. Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Kushner BH; Heller G; Kramer K; Cheung NK Cancer; 2000 Nov; 89(10):2122-30. PubMed ID: 11066054 [TBL] [Abstract][Full Text] [Related]
8. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia. Ghalaut PS; Sen R; Dixit G J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972 [TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861 [TBL] [Abstract][Full Text] [Related]
12. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia]. Murakawa Y Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645 [TBL] [Abstract][Full Text] [Related]
14. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098 [TBL] [Abstract][Full Text] [Related]
15. Subcutaneous versus intravenous granulocyte colony stimulating factor for the treatment of neutropenia in hospitalized hemato-oncological patients: randomized controlled trial. Paul M; Ram R; Kugler E; Farbman L; Peck A; Leibovici L; Lahav M; Yeshurun M; Shpilberg O; Herscovici C; Wolach O; Itchaki G; Bar-Natan M; Vidal L; Gafter-Gvili A; Raanani P Am J Hematol; 2014 Mar; 89(3):243-8. PubMed ID: 24178750 [TBL] [Abstract][Full Text] [Related]
16. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy. Wong SF; Chan HO Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284 [TBL] [Abstract][Full Text] [Related]
17. Effects of prophylactic hematopoietic colony stimulating factors on stem cell transplantations: meta-analysis. Kim S; Baek J; Min H Arch Pharm Res; 2012 Nov; 35(11):2013-20. PubMed ID: 23212644 [TBL] [Abstract][Full Text] [Related]
19. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Carlson JW; Fowler JM; Saltzman AK; Carter JR; Chen MD; Mitchell SK; Dunn D; Carson LF; Adcock LL; Twiggs LB Gynecol Oncol; 1994 Dec; 55(3 Pt 1):415-20. PubMed ID: 7530677 [TBL] [Abstract][Full Text] [Related]
20. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]